financetom
Business
financetom
/
Business
/
Update: Dave Shares Decline as Company Denies Wrongdoing in DOJ Complaint
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Dave Shares Decline as Company Denies Wrongdoing in DOJ Complaint
Dec 31, 2024 8:17 AM

10:46 AM EST, 12/31/2024 (MT Newswires) -- (Updates with stock price movement in the headline and first paragraph.)

Dave ( DAVE ) shares were down 9% in recent trading Tuesday after the company denied Justice Department allegations of misleading customers with promises of cash advances, calling the complaint a case of "government overreach."

The Department of Justice said Monday it filed a complaint against Dave ( DAVE ) and Chief Executive Jason Wilk alleging that the company lured customers to its personal finance app by advertising cash advances of up to $500 that many would not receive.

"We believe that we have always acted within the law, and we have continued to rely on the fact that other government agencies have previously reviewed the company's business model without taking action," Dave ( DAVE ) said.

In relation to the complaint, Dave ( DAVE ) said it will implement a new fee structure on its platform in early 2025 that eliminates optional tips and express fees for the ExtraCash offering.

Price: 85.87, Change: -8.59, Percent Change: -9.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alvotech Full-Year 2023 Loss Narrows, Revenue Rises
Alvotech Full-Year 2023 Loss Narrows, Revenue Rises
Mar 20, 2024
04:45 PM EDT, 03/20/2024 (MT Newswires) -- Alvotech ( ALVO ) reported a full-year 2023 loss late Wednesday of $2.43 per diluted share, narrower than a loss of $2.60 a year earlier. Four analysts surveyed by Capital IQ expected a loss of $1.09. Revenue for the year ended Dec. 31 was $93.4 million, up 10% from a year earlier. Analysts...
Myriad Genetics Gets US Patent for SneakPeek Snap Device
Myriad Genetics Gets US Patent for SneakPeek Snap Device
Mar 20, 2024
04:42 PM EDT, 03/20/2024 (MT Newswires) -- Myriad Genetics ( MYGN ) said late Wednesday the US Patent and Trademark Office granted it a patent covering the use of its blood-collection devices to determine fetal sex. The patent protects the company's SneakPeek Snap products in the country through at least 2040, Myriad said, and it also covers technology to improve...
Guess? Stock Climbs On Q4 Results: EPS Beat, Revenue Beat, Special Cash Dividend
Guess? Stock Climbs On Q4 Results: EPS Beat, Revenue Beat, Special Cash Dividend
Mar 20, 2024
Guess?, Inc. ( GES ) reported its fourth-quarter financial results after the bell Thursday. Here's a look at the highlights. The Details: Guess? reported quarterly earnings of $2.01 per share which beat the analyst consensus estimate of $1.56 by 28.85%. Quarterly sales clocked in at $891.05 million, beating the analyst consensus estimate of $855.54 million by 4.15% and representing an...
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca
Mar 20, 2024
04:44 PM EDT, 03/20/2024 (MT Newswires) -- Fusion Pharmaceuticals ( FUSN ) late Wednesday reported a Q4 net loss of $0.39 per diluted share, compared with a $0.55 loss a year earlier. Analysts polled by Capital IQ expected a loss of $0.33. The company did not report any revenue for the quarter ended Dec. 31 compared with $140,000 a year...
Copyright 2023-2025 - www.financetom.com All Rights Reserved